R73; Objective:Postmenopausal women with breast cancer are at increased risk of bone loss because of age related estrogen deficiency face which accelerated with the use of aromatase inbibitors (AIs).We aimed to study the effect on bone mineral density (BMD) and bone formation biomarker osteocalcin level in postmenopausal breast cancer patients,for the first three years of adjuvant hormonal treatment of both groups Tamoxifen versus Anastrozol.Methods:One-hundered postmenopausal breast cancers were prospectively randomized to receive either Tamoxifen 20 rag/day (n=50) or Anastrozole 10 mg (n=50).Both BMD and osteocalcin were assessed initially before treatment and then at regular intervals for both groups.Results:Use of Tamoxifen was associated with significant annual decrease in osteocalcin (P=0.001),whereas Anastrozole group had gradual increase of the annual levels (P＜0.01).BMD decreased significantly in Anastrozole versus Tamoxifen groups (2.6% vs.0.4%,P＜0.001).Osteoporosis T＜-2.5 was reported significantly

The Chinese-German journal of clinical oncology

Anastrozole; Tamoxifen,bone mineral density (BMD); breast cancer; osteocalcin